{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T23:15:07Z","timestamp":1722467707579},"reference-count":22,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.3892\/or.2013.2773","type":"journal-article","created":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T12:59:52Z","timestamp":1380632392000},"page":"2672-2676","source":"Crossref","is-referenced-by-count":4,"title":["Protein expression and subcellular localization of familial acute myelogenous leukemia-related factor"],"prefix":"10.3892","volume":"30","author":[{"given":"YUANMAO","family":"HUANG","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LULU","family":"CHEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MEILING","family":"YE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SHENGLONG","family":"LIN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YOUMEI","family":"ZI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SHAOYUAN","family":"WANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2013,10,1]]},"reference":[{"key":"key20180107224045_b1-or-30-06-2672","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fonc.2012.00040","article-title":"Genomics of acute myeloid leukemia: the next generation","volume":"2","author":"Riva","year":"2012","journal-title":"Front Oncol"},{"key":"key20180107224045_b2-or-30-06-2672","doi-asserted-by":"crossref","first-page":"5078","DOI":"10.1200\/JCO.2008.17.5554","article-title":"Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study","volume":"26","author":"Marcucci","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20180107224045_b3-or-30-06-2672","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa074306","article-title":"Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia","volume":"358","author":"Schlenk","year":"2008","journal-title":"New Engl J Med"},{"key":"key20180107224045_b4-or-30-06-2672","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1182\/blood.V80.10.2584.2584","article-title":"Expression of the FMS\/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages","volume":"80","author":"Birg","year":"1992","journal-title":"Blood"},{"key":"key20180107224045_b5-or-30-06-2672","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1182\/blood-2005-09-3640","article-title":"Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study","volume":"107","author":"Cairoli","year":"2006","journal-title":"Blood"},{"key":"key20180107224045_b6-or-30-06-2672","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood-2005-03-1323","article-title":"No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials","volume":"106","author":"Gale","year":"2005","journal-title":"Blood"},{"key":"key20180107224045_b7-or-30-06-2672","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/j.1365-2141.2008.07132.x","article-title":"Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals","volume":"141","author":"Ommen","year":"2008","journal-title":"Br J Haematol"},{"key":"key20180107224045_b8-or-30-06-2672","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"Dohner","year":"2010","journal-title":"Blood"},{"key":"key20180107224045_b9-or-30-06-2672","doi-asserted-by":"crossref","first-page":"984","DOI":"10.6004\/jnccn.2012.0103","article-title":"Acute myeloid leukemia","volume":"10","author":"O'Donnell","year":"2012","journal-title":"J Natl Compr Cancer Netw"},{"key":"key20180107224045_b10-or-30-06-2672","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1182\/blood-2008-08-172726","article-title":"Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide","volume":"11","author":"Karp","year":"2009","journal-title":"Blood"},{"key":"key20180107224045_b11-or-30-06-2672","doi-asserted-by":"crossref","first-page":"9394","DOI":"10.1158\/0008-5472.CAN-08-2815","article-title":"Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor perifosine in acute myelogenous leukemia cells","volume":"68","author":"Tazzari","year":"2008","journal-title":"Cancer Res"},{"key":"key20180107224045_b12-or-30-06-2672","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.leukres.2005.10.025","article-title":"A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse","volume":"30","author":"Moore","year":"2006","journal-title":"Leuk Res"},{"key":"key20180107224045_b13-or-30-06-2672","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/sj.leu.2404593","article-title":"Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines","volume":"21","author":"Furukawa","year":"2007","journal-title":"Leukemia"},{"key":"key20180107224045_b14-or-30-06-2672","first-page":"533","article-title":"Identification of differentially expressed genes in familial acute myelogenous leukemia by suppression subtractive hybridization","volume":"87","author":"Zhang","year":"2007","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"key20180107224045_b15-or-30-06-2672","first-page":"2245","article-title":"Full-length cloning of a novel gene, ELF2C, related to familial acute myelo-genous leukemia","volume":"87","author":"Wang","year":"2007","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"key20180107224045_b16-or-30-06-2672","first-page":"2667","article-title":"Full-length cDNA cloning and biological function analysis of a novel gene FAMLF related to familial acute myelogenous leukemia","volume":"88","author":"Li","year":"2008","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"key20180107224045_b17-or-30-06-2672","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/ng.913","article-title":"Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia","volume":"43","author":"Hahn","year":"2011","journal-title":"Nat Genet"},{"key":"key20180107224045_b18-or-30-06-2672","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1365-2141.2012.09136.x","article-title":"Marked genetic heterogeneity in familial myelodysplasia\/acute myeloid leukaemia","volume":"158","author":"Holme","year":"2012","journal-title":"Br J Haematol"},{"key":"key20180107224045_b19-or-30-06-2672","doi-asserted-by":"crossref","first-page":"5583","DOI":"10.1182\/blood-2008-07-168260","article-title":"High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder","volume":"113","author":"Preudhomme","year":"2009","journal-title":"Blood"},{"key":"key20180107224045_b20-or-30-06-2672","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/leu.2008.294","article-title":"Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation","volume":"23","author":"Renneville","year":"2009","journal-title":"Leukemia"},{"key":"key20180107224045_b21-or-30-06-2672","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/leu.2009.87","article-title":"A novel pedigree with heterozygous germline RUNX1 mutation causing familial MDS-related AML: can these families serve as a multistep model for leukemic transformation?","volume":"23","author":"Ripperger","year":"2009","journal-title":"Leukemia"},{"key":"key20180107224045_b22-or-30-06-2672","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/leu.2011.64","article-title":"Allogeneic stem cell transplant to eliminate germline mutations in the gene for CCAAT-enhancer-binding protein \u03b1 from hematopoietic cells in a family with AML","volume":"25","author":"Stelljes","year":"2011","journal-title":"Leukemia"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2013.2773\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T03:49:17Z","timestamp":1596599357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2013.2773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,1]]},"references-count":22,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2013,10,1]]},"published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.3892\/or.2013.2773"],"URL":"https:\/\/doi.org\/10.3892\/or.2013.2773","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,1]]}}}